Biodesix's PCP Bet Pays Off: Double-Digit Volume Growth and a Path to Profitability
Q2 2026 revenue up 34%, operating leverage improves, but the real story is the surge in primary care adoption.
BDSX · Earnings Call · 2026-08-05
Strong Quarter, Stronger Trajectory
We delivered another quarter of strong growth, expanding margins, and improving operating leverage, reflecting the strength of our commercial strategy as we continue to progress towards profitability.
That's how CEO Scott Hutton opened Biodesix's Q2 2026 call, and the numbers back him up. Total revenue hit $26.9 million, up 34% year-over-year, while diagnostic testing revenue surged 42% on 38% higher test volumes. Gross margin reached 82%, a 200-basis-point improvement, and adjusted EBITDA loss narrowed by 56%. The company has now posted five consecutive quarters of gross margin at or above 80%, a clear sign that its operational leverage is no longer a promise—it's a pattern. Total revenue has grown from roughly $4 million in 2019 to a $26 million quarterly run rate, with the latest call showing $26.9 million—a sustained climb that underscores the volume-led growth story.
The momentum is being driven not just by volume but by improved average revenue per test. CFO Robin Cowie attributed this to additional payer coverage and revenue cycle management improvements, continuing a trend that began in late 2025. Operating expenses outside direct costs grew only 7% against 34% revenue growth, highlighting the operating discipline that's bringing the company closer to sustained profitability.
The Primary Care Inflection
Perhaps the most notable development is the acceleration in primary care ordering. Primary care volumes grew 133% year-over-year, and total test volumes grew 38%, with both new and existing physicians using Nodify CDT and Notify Lung across the nodule continuum. The publication in March of the largest lung nodule biomarker validation study—showing Nodify CDT detects cancer in nodules as small as 4mm—has become a catalyst. As Hutton explained in Q&A:
“Yes, we do. We think post-publication what we've seen here is kind of the new trend and trajectory. The one thing that we know is that early detection and diagnosis matters. That was where that interest in the smaller nodules really originated. And we've seen great traction both for new customers and existing customers in adopting both.” — Scott Hutton, Chief Executive Officer · 2026-08-05
This is a continuation of a strategy that has been building for several quarters. On the Q1 call in May, Hutton noted that the PCP initiative was already showing early promise: “It has been about three quarters since we brought on that first sales cohort focused on primary care physicians, so you nailed it. We continue to learn, but we had some immediate learnings that we have been able to apply.” — Scott Hutton, Chief Executive Officer · 2026-05-04 That pilot evolved into the current expansion, with the company now averaging 104 sales reps in the field and planning to end the year at around 120. When asked whether a more aggressive expansion might be warranted, Hutton remained measured: “We continually assess what it may look like to opportunistically expand the sales force more rapidly, but you nailed it. We're very cost-conscious, we're mindful of where we are on that path to profitability... So yes, we're going to continue to be mindful about when and where we spend money.” — Scott Hutton, Chief Executive Officer · 2026-08-05
The financial discipline is paying off. Adjusted EBITDA loss improved 56% year-over-year, and the company's cash balance rose to $30 million, a 17% sequential increase, helped by $6.5 million in ATM proceeds. Excluding those, net cash use fell 70% year-over-year to just $2.1 million. The commercial team is scaling efficiently, and the company maintains its full-year revenue guidance of $108–$114 million.
Why This Matters
Biodesix is executing on a clear strategy: build out the primary care channel, leverage clinical evidence to expand adoption, and drive toward cash flow breakeven. The stock has responded—up 102.8% in the last 90 days, a dramatic reversal from a deep drawdown. The fundamentals support the narrative: Net loss has narrowed from more than $19 million in 2023 to a $7.3 million loss in Q2 2026, a 37% improvement year-over-year.
The real catalyst, though, may be on the horizon. CHEST guidelines—the standard for lung nodule management—haven't been updated in over a decade. Management is positioning a growing body of clinical and economic evidence to support inclusion of blood-based biomarkers. As Hutton said, "We feel that we've built a really strong data package" (component_hash: 4719917750362183101). If guidelines shift, the market opportunity could expand dramatically.
For now, the company remains focused on controlled growth and profitability. The combination of strong volume growth, margin expansion, and a clear path to breakeven makes this a name worth watching in the diagnostic space. As Hutton noted, "There's not an abundance of diagnostic companies that have gotten to profitability and then stayed there." Biodesix aims to be one of the few.